What is Anatomic Pathology Market?
Anatomic Pathology is the process of the observation of the organs and tissues to help in knowing the reasons and effects of particular diseases. Anatomic pathology involves the diagnosis of various types of cancer, infectious diseases, and medical conditions through the examination of cells and tissue samples, which are collected from patients through biopsy. The market is witnessing high growth due to an increasing prevalence of chronic diseases and increasing healthcare expenditure. The anatomical pathologist’s conclusions are essential to medical diagnosis, patient management, and research.
Highlights from Anatomic Pathology Market Study
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
Unit | Value (USD Million) |
Key Companies Profiled | F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Hologic, Inc. (United States), Koninklijke Philips N.V.( Netherlands), Agilent Technologies (United States), Becton, Dickinson, and Company (United States), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (United States), Diapath S.p.A. (Italy) and BioGenex Laboratories (United States) |
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anatomic Pathology market throughout the forecasted period.
F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Hologic, Inc. (United States), Koninklijke Philips N.V.( Netherlands), Agilent Technologies (United States), Becton, Dickinson, and Company (United States), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (United States), Diapath S.p.A. (Italy) and BioGenex Laboratories (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Oxford Cancer Biomarkers Ltd. (United Kingdom), Enzo Biochem Inc. (United States) and Epic Sciences (United States). Anatomic Pathology Market Segmentation:
Scope | Sub-Segments |
---|
Application / End User | Diseases Diagnosis, Drug Discovery & Development and Other Applications |
Type | Instruments (Tissue Processors, Microtome, Cryostats, Others), Consumables (Reagents(Stains & Dyes,Fixatives,Others), Antibodies) and Histopathology |
End User | Pathology Labs,Research Institutes,Hospitals,Others |
On the basis of geography, the market of Anatomic Pathology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Emerging Technology in Medical Device and Reagent Rental Agreements
Market Growth Drivers:
Rising Prevalence of Chronic Diseases and Growing Demand for Personalized Medicine
Challenges:
Lack of Skilled Professionals
Restraints:
High Degree of Consolidation in this Industry and Stringent Government Regulations Pertaining to Anatomic Pathology
Opportunities:
High-quality Infrastructure for Hospitals and Clinical Laboratorie and Increasing Number of Clinical Trials Pertaining to Cancer Drugs
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Anatomic Pathology Instrument Manufacturer, Anatomic Pathology Instrument Suppliers/Distributors, Raw Material Suppliers, Pathology Service Provider, Government Regulatory and Research Organizations and End-Use Industry
Market Leaders & Development Strategies
In Jan 2018, Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has acquired Pittsburgh, PA-based Omnyx from GE Healthcare.
In Oct 2018, Henry Ford Health System Pathology and Laboratory Medicine announced a research and development partnership with Sakura Finetek USA to increase the automation level of its core anatomic pathology laboratories, thereby increasing the quality of results while reducing turnaround time, minimizing errors, and lessening the need for human intervention.